Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results

Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million —— Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline dat…